With global prevalence estimates exceeding 30%, steatotic liver diseases represent the face of modern clinical hepatology, fomented by an environment that fosters poor nutritional choices and sedentary lifestyles.1 This public health scourge demands strategies focused on the early detection of liver disease, prognostication, and, importantly, disease modification to limit the morbidity and mortality associated with cirrhosis, organ failure, transplantation and hepatocellular carcinoma (HCC). Historically, liver outcome prediction required liver biopsy and hepatic venous pressure gradient (HVPG) assessment to determine clinically significant portal hypertension (CSPH).
Elangovan et al. (Fri,) studied this question.